Following anti-PD1 treatment, MASH also promoted aberrant activation of PD-1 + CD8 + T cells, leading to tissue damage, immune anergy, and reduced response to immunotherapy in preclinical HCC models [181]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.